Harrow, Inc. $HROW Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in shares of Harrow, Inc. (NASDAQ:HROW) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,921,683 shares of the company’s stock after acquiring an additional 50,889 shares during the period. Vanguard Group Inc. owned approximately 5.19% of Harrow worth $94,162,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blackhawk Capital Partners LLC acquired a new position in Harrow during the third quarter worth $5,272,000. Penn Capital Management Company LLC acquired a new stake in Harrow in the third quarter valued at $15,717,000. LJI Wealth Management LLC acquired a new stake in Harrow in the third quarter valued at $1,445,000. Luxor Capital Group LP acquired a new stake in Harrow in the third quarter valued at $14,807,000. Finally, Lumbard & Kellner LLC acquired a new stake in Harrow in the third quarter valued at $4,281,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Stock Up 2.8%

Harrow stock opened at $29.83 on Thursday. The company has a debt-to-equity ratio of 10.30, a quick ratio of 2.06 and a current ratio of 2.48. Harrow, Inc. has a fifty-two week low of $24.62 and a fifty-two week high of $54.85. The stock’s fifty day moving average is $36.83 and its two-hundred day moving average is $42.26. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -72.75 and a beta of 0.34.

Harrow (NASDAQ:HROW) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The company had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. During the same quarter in the prior year, the company earned ($0.38) earnings per share. Analysts predict that Harrow, Inc. will post 0.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Cantor Fitzgerald lowered their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a report on Wednesday. Nomura lowered Harrow to a “neutral” rating in a report on Wednesday, March 18th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Harrow in a report on Thursday, March 19th. BTIG Research reissued a “buy” rating and issued a $63.00 target price on shares of Harrow in a report on Tuesday. Finally, Zacks Research raised Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $69.43.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.